When does the miglustat patent expire?
Miglustat (Zavesca) is an older small-molecule medicine. Public patent-expiry timelines depend on the country, the specific patent family (drug substance vs. formulation vs. second medical uses), and the kind of exclusivity being counted (patents vs. regulatory data exclusivity vs. market authorisation exclusivity). The provided information doesn’t include any jurisdiction-specific patent or exclusivity dates for miglustat, so a precise “expiry date” can’t be stated accurately here.
How do you find miglustat’s exact patent expiry date for your country?
To get the correct expiry, you generally need three inputs:
1) the target country (e.g., US, UK, EU member state, India, etc.),
2) the product/marketing authorisation holder and strength(s) (so you match the right filings), and
3) which exclusivity is relevant (patent term vs. supplementary protections vs. data/exclusivity periods).
With that, you look up the patent family in the relevant national/regional patent registers and then confirm whether any extensions exist (for example, via supplementary protection mechanisms) and whether any later-use patents are still active.
Could generic or biosimilar miglustat launch before patent expiry?
Miglustat is a small molecule, so the usual “biosimilar” pathway doesn’t apply. If generics are approved, they typically follow either:
- a patent challenge/expiry event, or
- an approval pathway that still allows marketing only after exclusivity/patent barriers end.
Whether a generic can enter before the “main” patent expiry depends on whether other patents covering the product still block marketing.
Why patent expiry dates differ across regions (EU vs US, etc.)?
Patent term is not uniform worldwide. Even if the original priority date is the same, the effective end date can shift due to:
- local filing timelines and prosecution outcomes,
- patent term adjustments/extensions in that jurisdiction,
- additional patents in the same family (including formulation or new-use claims),
- differences between patent expiry and regulatory exclusivity.
If you tell me your country, I can narrow it down
If you share the country (or a specific regulator/market, like “EU-wide” or “UK”), I can help you identify which patent family entries to check and how to interpret the result into an actionable “earliest possible entry/marketing” date.
Sources
No sources were provided with the question, so I can’t cite any patent or exclusivity dates for miglustat here.